Can-Fite Biopharma (CANF) vs Lantern Pharma (LTRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Can-Fite Biopharma (CANF) has outperformed Lantern Pharma (LTRN) over the past year, losing 75.3% versus a loss of 91.9%. Over five years, LTRN leads with a -97.3% price change compared with -99.4% for CANF. Can-Fite Biopharma is the larger company by market cap ($4.4 million vs $3.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CANF | LTRN |
|---|---|---|
| Share price | $1.44 | $0.245 |
| Market cap | $4.35M | $3.89M |
| 1-day change | -2.34% | -13.73% |
| YTD return | -64.13% | -91.91% |
| 1-year return | -75.26% | -91.89% |
| 5-year return | -99.42% | -97.27% |
| EPS (TTM) | $-13.23 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $405.00K | — |
| Revenue growth (YoY) | -39.91% | — |
| Net income (latest FY) | $-9.83M | $-17.12M |
| Operating margin | -2456.79% | — |
| Net margin | -2426.67% | — |
| 52-week high | $10.40 | $4.34 |
| 52-week low | $1.42 | $0.2286 |
| Distance from 52-week high | -86.20% | -94.35% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +457.49% | +7042.86% |
| Average volume | 375.00K | 249.66K |
| Shares outstanding | 3.03M | 15.89M |
| Employees | 5 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CANF has outperformed LTRN by 16.6 percentage points over the past year.
About Can-Fite Biopharma
CANF stock →Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
CANF vs LTRN FAQ
Which is bigger, Can-Fite Biopharma or Lantern Pharma?
Can-Fite Biopharma (CANF) is larger, with a market capitalization of $4.35M compared with $3.89M for Lantern Pharma (LTRN).
Which stock has performed better over the past year, CANF or LTRN?
CANF returned -75.26% over the past 12 months, compared with -91.89% for LTRN (price return, excluding dividends). Past performance does not predict future results.
Are Can-Fite Biopharma and Lantern Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.